The Challenge of Anticoagulation: Getting Research Into Practice

Closing Remarks

Activity Details
  • Credit Type: Other
  • Credit Amount: 0.25
  • Cost: Free
  • Release: May 3, 2017
  • Expires: May 2, 2020
  • Estimated Time to Complete:
    15 Minutes
  • System Requirements:
  • Average User Rating:
    ( Ratings)

Faculty

Christopher B.  Granger Christopher B. Granger, MD, FACC, FAHA
Professor, Medicine, Cardiology
Duke University
Director, Cardiac Care Unit
DukeHealth
Durham, North Carolina

Needs Statement

VTE is a potentially preventable and treatable condition with the use of anticoagulation therapy. Management aims to reduce mortality and the risks of recurrence and long-term complications. The risk of recurrence is highest in the first 6-12 months after cessation of anticoagulant therapy but a heightened risk persists for at least ten years. Up to 25% of all VTE events occur in those with a previous event. Patients with unprovoked VTE have a higher risk for recurrence than those with VTE provoked by transient risk factors such as major surgery, trauma, acute medical illness, and others. Morbidity and mortality increase with each VTE recurrence and anticoagulation, the foundation of VTE therapy, can cause major bleeding which contributes to the morbidity and mortality.

The recently published 10th edition of the American College of Chest Physicians’ antithrombotic (AT10) guidelines (Kearon et al. Chest 2016; 149(2):315-352) outline the evolving role of non-vitamin K antagonist anticoagulants (NOACs) in the management of VTE including new recommendations on the treatment of cancer-associated thrombosis. However, there are many clinical scenarios where evidence is limited and, therefore, the management of VTE frequently carries significant clinical challenges. These challenges highlight the importance of educational forums to discuss clinical-decision process making based on the most recent evidence. Insights from registries - bridging the gap between contemporary research and clinical practice.

.

Target Audience

Health care professionals who are faced with challenges of anticoagulation treatment including the management of patients with VTE and/or patients with atrial fibrillation. These include practicing cardiologists, hematologists/oncologists, and geriatricians as well as specialists in Emergency Medicine, Internal Medicine, and all other subspecialist clinicians interested in anticoagulant therapy.

Objectives

Upon completion of this educational activity, participants will be able to:

  • Discuss appropriate therapy for VTE

Accreditation

Other
UK Healthcare CECentral certifies this activity for 0.25 hours of participation.

Faculty Disclosure

Christopher B. Granger, MD, (Planner and Speaker) has relevant financial relationships with commercial interests as follows:
Armetheon - Principal Investigator, Research Support, Salary Support
AstraZeneca - Principal Investigator, Consultant & Other Services, Research Support, Consulting Fee
Bayer - Principal Investigator, Consultant & Other Services, Salary Support, Consulting Fee
Boehringer Ingelheim - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Bristol Myers Squibb - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Eli Lilly - Consultant & Other Services, Consulting Fee
Daiichi Sankyo - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
FDA - Principal Investigator, Research Support
Gilead - Consultant & Other Services, Consulting Fee
Glaxo SmithKline - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Hoffman-La Roche - Consultant & Other Services, Consulting Fee
Janssen Pharmaceuticals - Principal Investigator, Research Support
The Medicines Company - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Medtronic Foundation - Principal Investigator, Research Support, Salary Support

Lord Ajay Kakkar, BSc, MBBS, PhD, FRCS, (Planner) has relevant financial relationships with commercial interests as follows:
Aspen Pharma, Bayer Healthcare, Boehringer Ingelheim Pharma, Daiichi Sankyo Europe, Sanofi SA - Consultant, Expert Testimony, Principal Investigator, Consultant Fee, Research Support, Honoraria

No other planners or reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

This activity is jointly provided by the University of Kentucky and Thrombosis Research Institute.

Supported by an unrestricted educational grant from Bayer.

FRONTLINE 2 Survey

The Fundamental Research in Oncology and Thrombosis (FRONTLINE 2) Survey is designed to evaluate how clinicians perceive the risk of venous thromboembolism in cancer patients and to provide insight into current strategies for thromboprophylaxis and management. It has been developed with the guidance of an international advisory board of experts in this field. This survey is coordinated by the Thrombosis Research Institute, London. It has been developed with the guidance of an international advisory board of experts in this field. All replies will be treated in the strictest confidence. The survey is split into 5 Sections (A-E) and will take approximately 20 - 30 minutes to complete.

To complete the survey, visit http://frontline2.tri-london.ac.uk/

CE Content Concerns

Policy

Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504

Procedures

  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.